PharmX Technologies (ASX:PHX) Other Long Term Assets: A$0.30 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PharmX Technologies Other Long Term Assets?

PharmX Technologies ASX:PHX Other Long Term Assets is A$0.30 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

PharmX Technologies's other long-term assets for the quarter that ended in Dec. 2025 was A$0.30 Mil.

PharmX Technologies's quarterly other long-term assets increased from Dec. 2024 (A$0.21 Mil) to Jun. 2025 (A$0.47 Mil) but then stayed the same from Jun. 2025 (A$0.47 Mil) to Dec. 2025 (A$0.30 Mil).

PharmX Technologies's annual other long-term assets declined from Jun. 2023 (A$0.53 Mil) to Jun. 2024 (A$0.32 Mil) but then increased from Jun. 2024 (A$0.32 Mil) to Jun. 2025 (A$0.47 Mil).

PharmX Technologies Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for PharmX Technologies's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmX Technologies Other Long Term Assets Chart

PharmX Technologies Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.80 0.71 0.53 0.32 0.47

PharmX Technologies Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.32 0.21 0.47 0.30

PharmX Technologies Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of A$0.30 Mil mean?
PharmX Technologies (ASX:PHX) has a Other Long Term Assets of A$0.30 Mil as of Dec. 2025. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on PharmX Technologies and its competitors.
Is PharmX Technologies' Other Long Term Assets too high?
PharmX Technologies' current Other Long Term Assets is A$0.30 Mil.
How does PharmX Technologies' Other Long Term Assets compare to VEEV and BTSG?
PharmX Technologies' Other Long Term Assets of A$0.30 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Healthcare Providers & Services company?
A good Other Long Term Assets depends on the Healthcare Providers & Services industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on PharmX Technologies and its competitors. PharmX Technologies's current Other Long Term Assets is A$0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.10 — trading 42.9% above its estimated fair value. The current Other Long Term Assets is A$0.30 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current Other Long Term Assets is A$0.30 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmX Technologies Business Description

Address 17 Castlereagh Street, Suite 11.02, Level 11, Sydney, NSW, AUS, 2000
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.